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ABSTRACT 
Protein drugs are typically administered intravenously, but this practice has clear 
disadvantages such as widespread circulation and swift clearance from the body.  Orally 
delivered protein drugs are not yet available but potentially offer improved distribution, 
retention, and activity by use of protective matrices and cell-specific targeting.  Much 
work has been done on delayed release formulations for the upper intestine, but there has 
not been overwhelming evidence of protection of peptides from gastric conditions.  In 
many instances the large intestine may be a better release target due to lower proteolytic 
activity.  Afflictions of the colon such as Inflammatory Bowel Disease and colon cancer 
would benefit most directly from colon targeted drug release. 
Orally delivered colon-targeted protein drugs need protection and a release mechanism to 
withstand the upper GI and be dispersed along the inflamed areas of the lower intestine.  
This sort of delayed release has been proven with low molecular weight drugs, but has 
yet to be shown with peptides which also need protection from the acidic and proteolytic 
conditions of digestion.  This work aims to distribute protein drugs throughout the colon 
while retaining protein activity. 
Pellets containing active peptides are synthesized from dextran modified with 
methacrylate.  Dextranase, formed by bacteria and found in increasing amount in the 
lower intestines, gradually degrades these pellets allowing steady transport of drug from 
the pellet.  These pellets are further coated in an acrylic copolymer (supplied by Evonik) 
designed to protect from acidic pH of the stomach and degrade within the upper 
intestines.  Polylactide nanoparticles loaded in these constructs were found to release 
steadily under conditions simulating the colon over 25-40 hours. 
Lysozyme was incorporated into pellets as a model protein drug and showed an estimated 
10% activity after a complete digestion simulation.  α-MUC1 was utilized similarly and 
imaged on epithelial cells, demonstrating feasibility of delivering antibody drugs orally.  
As many cancers overexpress MUC1 and inflamed cells are believed to as well, MUC1 is 
a potential drug target for CD and colitis.  In vivo data using a mice colitis model showed 
mitigation of symptoms when administered with antacids.  Overall this drug delivery 
platform has demonstrated colon targeting and potential efficacy of orally delivered 
enzyme, antibody, and other complex peptide drugs. 
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SPECIFIC AIMS 
 
Crohn's Disease (CD) and other forms of Inflammatory Bowel Disease (IBD) are 
characterized by chronic inflammation of the gastrointestinal tract and cause distress to an 
estimated 1.4 million Americans.  Current treatments include 5-aminosalicyclic acid as a first 
step and corticosteroids as an additional measure.  Newer treatments aim to inhibit 
mechanisms within the inflammatory response, most notably by blockers of TNF-alpha 
(Infliximab).  These drugs are approached with caution as they can only be administered 
intravenously, causing a systemic immune suppression and vulnerability to serious infections 
such as tuberculosis, fungal infections, urinary tract infections, and lymphoma.  Newer drugs 
which also serve as blocks in the inflammation cascade, such as complement inhibition, will 
also need to be injected and can be expected to have the same problems stemming from 
systemic immune suppression.  A more localized drug delivery is desirable for limiting these 
effects, and in this case oral delivery will be quite convenient by bringing drug to the colon 
directly without high circulation levels.  Protein drugs are not yet available orally as they are 
susceptible to degradation during digestion and inefficient release profiles, but with 
appropriate degradable hydrogels and protective coatings it should be possible to maintain 
some protein activity for effective disease treatment. 
 
Goal 1:  Develop a drug release system which releases gradually and specific to only colon 
conditions. 
 
Drug delivery should target the colon with great efficiency, with no drug released early into 
the stomach or upper intestine and no drug being passed with the stool.  As lesions could be 
present at any point in the colon, a gradual drug release is best to cover all areas and this 
requires 24-48 hours.  Hydrogel made from a modified dextran is the basis of the system and 
drug release is dependent on colon-specific enzymes.  Drug release profile was modeled with 
a release of nanoparticles from the gels. 
 
Goal 2:  Demonstrate protein efficacy after digestion simulation with enzyme and antibody 
examples 
 
Measurable protein activity after digestion simulation indicates that the drug delivery system 
is capable of releasing active peptides at the disease sites.  In separate experiments lysozyme 
and α-MUC1 were loaded into the dextran hydrogels which were coated with a pH-protective 
acrylic polymer.  After digestion simulation and drug release by dextranase, the final 
products were tested for antibacterial activity and epithelial cell attachment, respectively. 
 
Goal 3:  Achieve remission of symptoms in an Inflammatory Bowel Disease animal model. 
  
A new drug combining complement inhibitor crry and complement breakdown product 
targeting moiety CR2 has been successful as an injection in mouse studies.  crryCR2 was 
delivered orally within very small particles of the coated dextran hydrogel to colitis-induced 
mice and the health measures of weight, colon length, and intestinal histology were 
compared.
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CHAPTER 1:  BACKGROUND 
 
Crohn’s Disease 
Crohn’s Disease (CD) is a form of Inflammatory Bowel Disease (IBD) characterized by 
mucosal inflammation in patches or lesions along the GI tract, while Ulcerative Colitis 
(UC) has similar symptoms but with inflammation starting within the colon and 
proceeding more continuously to the rectum.   Symptoms remit and return unpredictably 
and include swelling in the intestine, abdominal pain, diarrhea, weight loss, and fever.  
Although remissions can last as long as years, there is no cure and the mechanism of IBD 
is still speculated[1].  It is well known that certain foods can aggravate symptoms in some 
patients, but no single type of food has been singled out.  The leading theory for the 
disease is an immune attack on bacteria, food, or other substance in the intestine.  The 
most common and conservative prescription for CD/UC is 5-aminosalicyclic acid (5-
ASA), an anti-inflammatory shown to inhibit pathways including PGE2, PGD2, IL-1, IL-
2 , TNF-α, and provide protection from reactive oxygen species [2].  It is available in 
topical and oral form and found to be most effective in combination.  Should this fail to 
induce remission, it is standard to prescribe corticosteroids, although the severity of side 
effects limits this method to a few months of use. 
Protein drugs are the key to future treatments, as cytokines and monoclonal antibodies are 
exceeding chemical drugs in anti inflammatory roles.  The most targeted component of 
the inflammation process is Tissue Necrosis Factor (TNF) alpha, such as Infliximab 
which is successful for many in treating CD, arthritis, and other autoimmune diseases[3].  
There are several different injected monoclonal antibodies which act as TNF alpha 
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blockers, but they all have similar problems.  With a major regulating factor of the 
immune system silenced, patients are at high risk of serious infection including urinary 
tract, fungal, and bacterial infections and elevated risk of lymphoma and cancer[4].  A 
different drug delivery platform is needed to make the most of TNF-alpha blockers and 
any new immune suppression cytokines. 
Desirability of Oral Administration 
The current drug delivery method for protein drugs is parenteral, whether given 
subcutaneously, intramuscularly, or intravenously.  While this is more direct and efficient 
than absorption in the digestive tract by enteral administration, the pharmacokinetics of a 
large, systemic dose can be far from ideal.  Following injection, a large amount of drug is 
widely distributed in the body, harming cells and tissues outside the targeted area of 
treatment.  The toxicity of a drug limits the peak concentration of the drug, which could 
mean a dose falls below a therapeutic concentration within a short time of injection.  Any 
injected drug will be cleared from the system by renal filtration, drug 
instability/insolubility, or immune recognition;  this can only be countered by higher, 
more toxic doses, inconveniently frequent doses, or a continuous infusion[5].   Concerns 
with toxicity, health risks, quality of life, and high demands on medical attention limit 
this type of action with injected drugs, especially for a chronic condition.  By using orally 
delivered enteral formulations, drug may be more gradually absorbed over a longer 
period, advantageous for permanent or chronic conditions.   
In the case of TNF-alpha blockers prescribed against CD and IBD, oral delivery can limit 
the side effects of systemic immune suppression by bypassing circulation and acting 
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primarily around the inflamed epithelial wall.   Newly developed treatments will likely 
also impede the immune system and would benefit for the same reason.  Proposing to 
deliver protein drugs orally requires a thorough look at the available drug delivery 
materials. 
Oral Protein Drug Delivery - Insulin 
Insulin has become the most studied protein drug for oral delivery.  With diabetes being a 
very common disease with huge commercial significance, insulin was one of the first 
proteins to be isolated in pure form and recombinantly cloned and produced.  Many of the 
materials for oral drug delivery were developed with oral insulin delivery as a goal.  
Approaches include prodrugs or substances that cleave chemically to produce insulin, 
encapsulation in microparticles, and loading in hydrogels of natural or synthetic 
polymers. Materials include poly(methacrylic-g-ethylene glycol) hydrogel 
microspheres[6, 7], calcium phosphate-insulin-PEG-casein particles[8], vitamin B12 
prodrugs[9], and chitosan-4-thiobutylamidine[10], to name a few.  All reports have 
shown some degree of potential, and several have shown a hypoglycemic effect in 
rodents lasting 8 or more hours.  However no oral format has proven sufficiently 
reproducible and dose-dependent in clinical trials, and new drug delivery materials are 
needed to increase both protein protection and bioavailability.   
Formulations for Oral Administration 
Oral drug formulations must maintain pellet integrity and isolate the contents from local 
conditions until the desired region of absorbance is reached.  Acrylic polymers are a 
common capsule coating for controlling drug release.  Sensitive to pH, they are 
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hydrophobic at low pH isolating the contents then swell, become porous, and delaminate 
over time as they become hydrophilic at higher pH.  There are many commercially 
available acrylic copolymers, and Evonik Industries offers a wide series based on the pH 
level of swelling and duration of that process.  There are even some extended release 
formulations which are slow enough to be marketed as colon targeting, but these depend 
on a pH of 7 or higher inside the intestines, which IBD patients may not reach[11-14] 
 
Eudragit L100-55 (supplied by Evonik Industries) is a commercial acrylic copolymer 
appropriate for this purpose, providing impermeability at low pH and gradual swelling at 
pH values over 5.5.  This coating is intended to isolate the pellet from stomach acid and 
start a gradual swelling in the duodenum, providing some degree of isolation from small 
intestine conditions before exposing the underlying hydrogel by the time of reaching the 
cecum. This is useful for IBD use as it doesn't depend on high intestinal pH like many 
extended release formulations.   Eudragit acrylic copolymers have been demonstrated to 
delay release when coated onto drug tablets, but the ability to protect peptides is yet to be 
fully proven[15, 16].    It is likely that the hydrophobicity of acrylic at low pH forms a 
protective barrier in acidic stomach conditions, and acrylic polymers have been suggested 
to inhibit the intestinal proteases chemotrypsin and trypsin to protect insulin[17].  In vitro 
experiments are needed to demonstrate the degree of peptide activity which can be 
retained by using these materials.   
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Fig 1.  Desirable characteristics for oral delivery materials.  The release profile must target the  
 desired area and peptide activity must be maintained for in vivo oral peptide delivery to   
 be feasible. 
 
Large Intestine Delivery 
Many pH dependent coatings and tablets have been reported[18-21], using the rise in pH 
from the stomach into the small intestine to initiate swelling which continues until the 
large intestine is reached and drug release rate increases.  While these products may be 
quite reliable in healthy and normal individuals, patients of Inflammatory Bowel Disease 
(IBD) and colon cancer experience lower pH in the intestinal lumens[11, 12] and widely 
varying gastric emptying times[22], which makes the proper release of drug 
impossible[14, 20, 21, 23].  Furthermore, in several studies the in vitro colon drug release 
can be at least partially contributed to changes other than pH such as a change in buffer 
systems[21, 23, 24].  With this knowledge we will turn to drug delivery systems with 
bioresponsive or biodegradable foundations, which may prove to be more flexible to 
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conditions.  The carbohydrate and protein-metabolizing enzymes released by colon-
specific flora can provide site-specific release by biodegradation. 
Biotransformation Capabilities of the Colon 
The enzymatic conditions within the colon can initiate azoreduction, hydrolysis, 
acetylation, ring opening, and many other chemical reactions[25].  Azoreduction is the 
most commonly utilized, activating prodrugs such as prontosil and neoprontosil.  The 
common Crohn’s Disease treatment 5-aminosalicylic acid is formed from acetylation of 
the prodrugs sulfasalazine, balsalazide, and olsalazine.  In addition to releasing active 
compounds from prodrugs, bacterial enzymes can be used for colon specific degradation 
of natural materials to initiate drug release, such as gels made the polysaccharides 
chitosan, guar gum, inulin, and dextran.   Polysaccharides are safe, inexpensive, nontoxic, 
can be readily chemically modified to reduce solubility and form crosslinked networks, 
and degrade well.  Chitosan has been made into gels and microcapsules to provide colon-
specific degradation but was found to dissolves quickly in acid[22, 26], requiring enteric 
coatings.  It has been encapsulated along with alginate and shown to protect 
bacteriophages in vitro[27] and used in thiolated form in insulin delivery studies [10].  
Much research on guar gums has been on reducing solubility, as the gels formed often 
have too high a swelling ratio to contain water soluble drugs but may work in delivering 
water insoluble drugs[28].  A colon-targeting material of azo-bonded methacrylated 
inulin hydrogel was intended to degrade by both inulinase and azoreductase, but was 
found to release drug entirely before reaching the large intestine[29].  Premature drug 
release from inulin gels was again observed in another more recent study, wherein the 
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rheological properties of methacrylated crosslinked inulin gels were extensively 
examined but were found to have an immediate burst release in the stomach[30].  While 
the premise of a polysaccharide gel for drug release remains attractive, most attempts 
have been found too unreliable for practical use. 
Dextran 
Dextran is among the most promising of these polysaccharides, having served as a 
prodrug anchor in well cited studies with naproxen[31] and ketoprofen[32], and recently 
for glucocorticoids [33].  The polysaccharide gels are safe enough for implantation, as 
gels of crosslinked dextran have seen success as implantable disks releasing EGF and 
bFGF in animal studies[34].  The availability, nontoxicity, and success in oral 
formulations make dextran an attractive candidate for a hydrogel-based oral drug delivery 
system, and the degradation of dextran is colon-specific by the bacterial enzyme 
dextranase . Dextran has been made into hydrogels in many accounts, usually modified 
with methacrylate for easy crosslinking [35-38] but occasionally using other methods like 
crosslinking with diisocyanate[39].  Between all of these studies with dextran hydrogels 
it was common to find a degree of swelling that allowed degradation while still 
preventing premature drug release, whereas this was difficult in studies with 
polysaccharide gels from other materials such as inulin and guar gum.  While some 
studies have already indicated colon-specific release, none have the gradual release 
desired in this project and the protection of peptide drugs has not been proven for these 
materials. 
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With chemical addition of vinyl groups, dextran can be made crosslinkable and hydrogels 
can be made.  By an epoxide ring opening reaction, glycidyl methacrylate groups can be 
substituted into the dextran backbone, creating crosslinkable methacrylated dextran: 
 
 
Fig 2.  Chemical substitution of glycidyl methacrylate groups onto dextran chains[38].  The 
 resulting product in crosslinkable and can be used to make hydrogels for drug delivery. 
 
This is the material developed by Dijk-Wolthuis  and used by several over recent 
decades.  The modified dextran can absorb drug by swelling in aqueous solutions and is 
crosslinkable using a free radical photoinitiator.  Rate of degradation is somewhat 
controllable by changing the degree of substitution of methacryl groups on the dextran 
backbone, thus changing the crosslinkability.  This material is responsible for containing 
the active drug and controlling its release.  For CD a gradual release is desired as lesions 
of inflammation can be anywhere in the colon, and for any drug with preventative 
purpose a thorough distribution is needed to ensure remission.  A desirable hypothetical 
release profile would begin release immediately in colon conditions and continue for at 
least 24 hours.  One study of dextran hydrogels has shown this but with using dextranase 
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concentrations far beyond physiological values[40], another study with different 
crosslinking method shows drug release as long as 50 hours[41].  None of these studies 
referenced has examined protein protection against digestion simulations. 
Protein Protection Assessments 
While dextran hydrogels have been shown to have desirable degradation and small 
molecule release properties, there has yet to be a demonstration of its ability to shield 
fragile contents from any acidic or enzymatic trial.   Acrylic coatings are also unproven 
but should help in this regard, as the hydrophobicity at low pH likely forms a protective 
barrier in acidic stomach conditions.  Acrylic polymers are also suggested to inhibit the 
intestinal proteases chemotrypsin and trypsin to protect insulin[17].   
 
Antibody Delivery 
Protection of orally delivered antibody drugs would enable monoclonal antibody drugs 
like Infliximab to be given orally.  It is likely that future and developing immune 
suppressants will take a similar form.   Research in antibody drug conjugates would also 
be enabled for the unique colon and inflammation conditions. The vast majority of 
antibody drug conjugate research has focused on targeting cancer cells with cytotoxic 
drugs from systemic circulation; however oral delivery can avoid rapid degradation and 
clearance of antibody drug conjugates while giving an improved localized distribution in 
diseases of the gastrointestinal system like colon cancer and IBD.  Establishing colon 
specific drug release is a good basis, but further adherence and retention on the epithelial 
wall can effectively increase the concentration and duration of a dose.  Due to the cost 
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and fragile nature of protein drugs, it is desirable to target all molecules as precisely as 
possible to make the most out of every dosage.   
 
Anti inflammatory or other mitigating drugs could be localized to affected epithelial cells 
by targeting moieties and be absorbed gradually through the mucosa, providing a more 
permanent drug presence and reduced side effects compared to large untargeted doses.  
One potential target is ICAM-1, a luminal cell adhesion molecule involved in adhesion 
and migration of neutrophils and monocytes, which is expressed during inflammation and 
IBD[42, 43].  CD68 targeting would bind to macrophages present at inflamed areas[44].   
The glycoprotein MUC1 was chosen for more investigation due to some unique 
properties described below. 
MUC1 
Systemic absorbance in the intestines is somewhat hampered by the slow transport across 
the mucus and water layers surrounding the epithelial layer[13], believed to cause poor 
bioavailability in some research[8, 10].   However for diseases like IBD and colon cancer 
these layers provide a natural substrate for prolonged retention, potentially evening out 
the local concentration of drug between doses and keeping the drug in proximity to 
affected epithelial areas.  MUC1 is a large, glycosolated protein expressed on the apical 
membrane healthy epithelial cells with an extracellular domain extending 300-500 nm 
from the cell, much further than the normal  glycocalyx[45].  MUC1 targeting is a 
popular approach in cancer research, as it is found to be overexpressed in over 50% of 
tumors[46].    The glycoprotein is also upregulated during infection and believed to play a 
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role in preventing infection of mucosal cells[47].  Overexpression has been also observed 
due to inflammation, leading many to speculate on the links between IBD and colon 
cancer[48].  This molecule is worthy of investigation as a ligand for colon inflammation 
targeting. 
Significance 
The current treatments for CD are insufficient to mitigate symptoms inflammation 
symptoms long term.  Immune suppression drugs like Infliximab and newer pathway 
inhibitors need improved drug distribution to limit side effects, which is why we turn to 
oral delivery.  Oral drug delivery systems currently available have been proven to delay 
release in a myriad of small molecule drug formulations, but nothing available fits the 
requirements for protein delivery.  Furthermore most developments have focused on 
insulin and not considered colon targeting.  Polysaccharide gels have colon-targeting 
potential, with crosslinked dextran being the most robust candidate.  Acrylic coatings 
may impart an additional level of isolation in acidic stomach conditions. 
 
Our proposed solution is a capsule base of methacrylated dextran, containing appropriate 
proteins in a hydrogel.  A capsule coating of methacrylate: ethyl acrylate alternating 
copolymer imparts some impermeability to acid and swells to delaminate in the upper 
intestines.  This formulation is intended to isolate contents from stomach and upper 
intestine conditions and release gradually through the length of the colon.  The type of 
release profile desired has never been shown for these specific materials and will need to 
be demonstrated in vitro. 
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 Peptide protection is critical for delivering active peptides, and studies with the dextran 
and acrylic materials chosen have not yet proven sufficient peptide protection . To 
quantify peptide protection the enzyme lysozyme was incorporated into coated pellets 
and tested for antibacterial activity after digestion simulations.  Further supporting data 
was found by treating an antibody to MUC1 in the same manner as lysozyme and 
assessing its binding.   
 
With appropriate release characteristics and sufficient protein protection demonstrated, 
this drug delivery system is capable of orally delivering a variety of therapeutic protein 
drugs.  To verify this, in vivo experiments in mice used drug loaded pellets to treat colon 
inflammation.  
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Fig 3:  Summary of goals and research methods (yellow boxes) for oral delivery of protein drugs with 
emphasis on IBD treatments. 
 
CHAPTER 2:  RESEARCH METHODS 
1.  Structure of Protective System 
The drug delivery system used in all experiments included dextran hydrogel and acrylic 
coating.  Methacrylated dextran and photoinitiator were added to protein solutions and 
polymerized into droplets by UV activation.  The resulting gels were covered in an 
aqueous suspension of acrylic copolymer 
 1.1   Dextran Modification 
Dextran gels were prepared using the procedure similar to that reported by Dijk-Wolthuis 
[38].  Dextran (MW 70,000) was coupled to glycidyl methacrylate to introduce vinyl 
group that is necessary for crosslinking dextran molecules. For coupling, glycidyl 
methacrylate and (N,N-dimethylamino) pyridine was added to dextran solution in 
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dimethylsulfoxide (DMSO). The solution was stirred at room temperature for 48 h. The 
product was isolated by 3 times rinsing with acetone solution followed by centrifugation. 
Modified dextran contained 4  methacrylic acid residues per 100 anhydroglucoside units 
(DS=4, determined by NMR spectra).  
1.2  Pellet Formation 
Lyophilized modified dextran (described in 1.1) was added to solutions of the relevant 
peptide to make a 25% dextran solution and AIBN was added at .75% of dry polymer 
weight.  The suspension was pipetted onto paraffin film to form hemispheres and 
crosslinked by UV lamp (365 nm, 84 watts) for 12 minutes, producing 20% wt dextran 
hydrogels. 
 1.3  Eudragit Coating 
Coating solution was an aqueous suspension of 12.5% Eudragit L100-55 with 6.25% talc 
to reduce tackiness and 1.5% triethyl citrate as a plasticizer.  Dextran hydrogels were 
coated in prepared Eudragit suspension, drained of excess, and the surfaces was dried 
briefly with warm air.  All pellets received three coats in this method. 
 1.4  Digestion Simulations 
All in vitro experiments used digestion simulations.  After coating had dried, the stomach 
was simulated by 1 hour in PBS pH 1.5 and the small intestines were simulated by 5 
hours in .1% trypsin.  In some experiments a range of milder conditions were also tested 
in the same method, as listed later in the experimental section.  The large intestine was 
simulated by the physiological level of .1 U/mL dextranase in neutral PBS for 
16 
 
determining the release profile, and all other experiments used .5U/mL dextranase for 3 
hours to release the final product for testing. 
 
2.  Nanoparticle Release Profile 
 Rationale 
This experiment determines the timecourse of drug release in the GI tract.  Hydrophilic 
nanoparticles were used as tracers because they are easily measured and do not degrade 
in the test conditions.  For this purpose we were  interested in release with regard to time 
and condition without interference from peptide degradation, so nanoparticles were more 
appropriate than proteins for tracers.  In early stages of the project, when this experiment 
was performed, nanoparticles were intended to be the base of a drug and targeting moiety 
complex.  Although none of the peptides used in this thesis involved nanoparticles, future 
work may see nanoparticles incorporated into the controlled release system.  As the 
release from the gels was believed to be more degradation-dependant than diffusion-
dependant, nanoparticles are appropriate for a universal measurement.   
2.1  PLA-PEG Nanoparticle Synthesis 
Rhodamine-labeled PLA-PEG nanoparticles were made from of 75% poly(DL-lactide) 
(Aldrich) and 25% poly(ethylene glycol)methyl ether-block-polylactide  (PLA ~5000 
Mn, PEG ~5000 Mn, Aldrich) dissolved in 99.7% purity acetone to make a solution of 
7.5 mg/mL polymer.  The acetone solution was added dropwise to sonicating DI water 
and sonicated a further 30 minutes (Branson 5510 sonicator).  Nanoparticles were sized at 
80 nm by particle size analysis, purified by 3 centrifugations, and suspended in DI water. 
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 2.2  Pellet Formation and Coating 
Modified dextran was added to a nanoparticle suspension as described in Methods 1.2 to 
make 50 uL hemispheres.  These were coated three times in the acrylic suspension as 
described in Methods 1.3 
 2.3  Digestion Simulation and Release Tracking 
The loaded pellets were subjected to the digestion simulation described in Methods 1.4 
for stomach and small intestine.  No measurements were made for these, as dye in the 
trypsin interfered with colorimetric readings. During colon simulation, the fluid above the 
pellets was tested for emission at 610 nm (Bio-Tek Synergy HT) and compared to 
nanoparticle suspensions to determine release percentage.  This ratio exceeded 1.0 but 
was normalized to 100%, as the pellet had degraded completely by the final time point.  
Every several hours, dextranase was renewed to maintain activity and new readings were 
added to the previous. 
3. Lysozyme Protection Assay 
 Rationale 
Previous work on either dextran hydrogels or acrylic coatings has never demonstrated 
protein protection, much less in a well quantified form.  The idea of this experiment is not 
to propose lysozyme as a therapy but as a model of enzyme delivery, incorporated into 
pellets and sustaining digestion to various observable and calculated degrees.  Retention 
of enzyme activity is an excellent indicator of the protection provided by the drug 
delivery system, considering that enzymes are more fragile than other peptide classes.  
Within the body enzymes are renewed constantly as their activity quickly fades.  Even 
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observing partial enzyme activity after facing digestion conditions will indicate success 
for more robust categories of proteins.   Lysozyme serves this role perfectly, being well 
studied, widely available, and possessing easily measured antibacterial activity. 
 3.1  Pellet Formation and Experimental Conditions 
Hydrogels were made from modified dextran in the same method described above except 
20 uL in size and containing .5 mg/mL lysozyme rather than nanoparticles.  All pellets 
were coated in as described in Methods 1.3  There were five different stomach and small 
intestine digestion simulation conditions tested: 
 
Treatment # 
Stomach 
Simulation (1 hr) 
Small Intestine 
Simulation (5 hr) 
Quick Colon 
Digestion (3 hr) 
1 none PBS 1U/mL Dextranase 
2 PBS pH 4 .1% Trypsin 1U/mL Dextranase 
3 PBS pH 4 PBS 1U/mL Dextranase 
4 PBS pH 1.5 .1% Trypsin 1U/mL Dextranase 
5 PBS pH 1.5 PBS 1U/mL Dextranase 
 
 3.2  Antibacterial Assay 
The final products were tested for antibacterial activity against Micrococcus 
lysodeikticus.  The quick colon digestion was observed to release no more than ½ of 
loaded particles, but was chosen because longer incubations would risk degradation of 
enzyme activity.  Based on this the control lysozyme solution was .025 mg/mL.  Stock 
Micrococcus suspension was added to 96 well plates for an initial OD of .6.  
Antibacterial activity was recorded by absorbance at 405 nm using Bio-Tek Synergy HT 
plate reader under continuous shaking.   
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4.  Antibody Protection Study 
 Rationale 
Similar to the Lysozyme Protection Assay, this study will indicate peptide protection.  In 
this case it is more relevant to mAb. drugs like Infliximab and to experimental targeting 
moieties.  anti-MUC1 was chosen for a ligand for its expression on epithelial cells, 
relevance to IBD, and its availability/familiarity in the lab.  Using α-MUC1 conjugation, 
it should be possible to target molecules to the epithelial wall with emphasis on the 
inflammation locations, where they will concentrate above the glycocalyx of epithelial 
cell and enhance retention between doses. α-MUC1 was incorporated into the drug 
delivery system, treated with digestion simulations, and tested for activity investigated by 
immunofluorescence and confocal microscopy.  The NHBE cells used for imaging 
originate from the airway not the intestine, but as both cell types express MUC1, NHBE 
was sufficient for this purpose.   
 4.1  Sample Preparation 
MUC1 primary antibody (rabbit polyclonal, Abcam, .2mg/mL) was incorporated into 
gels and coated or left unprotected and subjected to various acidic and trypsin treatments 
to simulate the stomach and small intestine stages of digestion.  The target concentration 
was a 1:50 dilution.  Large intestine incubation used a high dextranase concentration to 
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dissolve pellets quickly for testing.  Final products were tested on fixed NHBE cells for 
MUC1 adherence.  The following table summarizes the sample groups: 
 
 
 
Stomach 
Incubation (1.5 hr) 
Small intestine 
incubation (5 
hr) 
Large intestine 
incubation (3 hr) 
Pellet Sample 1 PBS pH 1.5 .1% trypsin 
2.5 U/mL 
dextranase 
Pellet Sample 2 PBS pH 4.0 .1% trypsin 
2.5 U/mL 
dextranase 
Pellet Sample 3 PBS pH 7.0 PBS pH 7.0 
2.5 U/mL 
dextranase 
Positive Control PBS pH 7.0 
Negative Control No Primary Ab. 
 
To verify the statement that the pellets had provided antibody protection, free MUC1 
antibody was subjected to the same conditions as Pellet Sample 1 and compared to 
positive and negative controls, as detailed: 
 
Stomach 
Incubation (1.5 hr) 
Small intestine 
incubation (5 
hr) 
Unprotected 
Antibody PBS pH 1.5 .1% trypsin 
Positive Control PBS pH 7.0 
Negative Control No Primary Ab. 
 
 4.2  Cell Preparation 
T75 flasks were coated with human placenta collagen for 4 hours before introducing 
normal human bronchial epithelial cells (NHBE, P3).  Cells were grown for 5 days at 37° 
and 5% CO2.  The media used was BEGM (Lonza) and was changed on the second day 
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and every two days afterward.  Cells were passaged into chambered coverglass using 
Accutase and trypsin inhibitor then left overnight before fixation and labeling. 
 4.3  Immunofluorescence Techniques 
All chambers of NHBE cells were fixed by 4% paraformaldehyde for 15 minutes.  
Samples as described above were added to constitute the primary incubation.  Blocking 
solution was 3% goat serum and 2% bovine serum albumin in 20 mM glycine PBS.  The 
secondary antibody was Alexa Fluor 488-labeled goat α-rabbit (Invitrogen) at 1:200 for 
30 minutes.  Between all steps cells were rinsed three times with 20 mM glycine PBS.  
All in vitro images were taken on a Nikon Eclipse TI. 
 
5.  CR2crry in vivo study 
  Rationale 
The protein CR2crry was developed by S Tomlinson and combines complement inhibitor 
crry with targeting moiety CR2, which attaches to breakdown products at sites of 
complement activation.  In murine autoimmune disease models it has been shown quite 
effective as low dose injections [49, 50].  While Infliximab would have been a more 
industrially relevant choice, this peptide is sufficient for in vivo demonstration because it 
is previously proven to reduce inflammation.  CR2crry requires digestion protection for 
its immune and cytokine components, so success with CR2crry would prove that the 
peptide protection is also sufficient for Infliximab.   
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This drug was incorporated into small pellets and administered orally to mice.  Symptoms 
of weight loss, colon shortening, and macrophage/neutrophil recruitment can be observed 
in rodents.  Preparation of all pellets was performed by myself while at MUSC, and all 
animal handling work and data collection was performed by Michelle Elvington and Fei 
Qiao at MUSC.  The experiment served the purposes of both parties so efficiency, 
expenses, and collaboration were part of the rationale. 
 5.1  Pellet Preparation 
Using a 12 mg/mL solution of CR2crry, 2 uL dextran hydrogels about 1mm in size were 
formed as described in Methods 1.2.   Control pellets were made omitting the CR2crry.  
Pellets were coated with Eudragit L100-55 as described in section 1.3 of Research 
Methods. 
 5.2  In Vivo Administration 
In vivo work was conducted by Michelle Elvington and Fei Qiao of Dr Tomlinson's lab at 
MUSC.  Ulcerative colitis was induced in mice with a dextran sodium sulfate (DSS) 
enema regime.  In sample groups using CR2crry or control pellets, 6 mice were given 3 
pellets per day for 5 days.  Certain sample groups used omeprazole as an antacid for 
supplementary drug protection.  Animal weight was recorded daily.  Upon animal 
sacrifice colon length was measured and histological samples were stained with 
hemotoxylin/eosin and scored on severity of inflammation, mucosal/submucosal damage, 
and basal lamina damage.  All 3 scores were added together for comparison between 
groups. 
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CHAPTER 3:  RESULTS AND DISCUSSION 
Nanoparticle Release 
Nanoparticle release was tracked over the lower intestine portion of digestion simulation 
only as the colorimetric reading could not be taken in the trypsin solution.  Considering 
that the expected full release was obtained and the acrylic coating lasted for most of the 
small intestine incubation, the release before colon conditions was negligible.  At 3 hour 
intervals, the dextranase solution was changed for freshly prepared solution due to fading 
enzyme activity.  After each exchange, fluorescence values were added to the previous 
cumulative release and compared to the control suspension.  Fluorescence values were 
compared to a control nanoparticle suspension representing full release to determine 
percent release at each time point.  Although this ratio exceeded 100%, it can be safely 
assumed that drug release finished at 100% as the pellets were dissolved completely at 
the final timepoint.  Although it may not have been accurate to treat the fluorescence 
values from the plate reader as linear and additive, this data is sufficient to show expected 
duration of drug release. 
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Fig 4.  Release of labeled nanoparticles from coated dextran hydrogel pellets during large intestine 
portion of digestion simulation relative to a control nanoparticle suspension. n=4 
 
The timeframe of release is suitable for dispersion throughout the lower intestine, as the 
25-40 hour release period normally parallels the transit time in the lower intestines.  A 
typical release could be expected to last at least 24 hours. This is a good baseline for 
delivery as it should cover a large area of the colon, but modifications are possible by 
varying the DS (degree of substitution) of methacryl groups on dextran, which will 
change the crosslinkability and likely the time for the hydrogel to digest.  This possibility 
can be explored if some patients need release over a shorter timeframe due to a faster 
gastric emptying time.  Ulcerative Colitis patients with inflammation extending beyond 
the reach of enema may benefit from using oral delivery with a more delayed release to 
emphasize more distal areas of the colon. 
Lysozyme Protection Assay 
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The antibacterial property of lysozyme is indicated by a drop in bacterial OD.  Samples 
are listed in the order of their activity: 
 
Treatment # 
Stomach 
Simulation (1 hr) 
Small Intestine 
Simulation (5 hr) 
Quick Digestion     
(3 hr) 
Control Lysozyme - - - 
1 none PBS 1U/mL Dextranase 
2 PBS pH 4 PBS 1U/mL Dextranase 
3 PBS pH 4 0.1% Trypsin 1U/mL Dextranase 
4 PBS pH 1.5 PBS 1U/mL Dextranase 
5 PBS pH 1.5 0.1% Trypsin 1U/mL Dextranase 
Control Cells - - - 
Table 2.  Lysozyme Protection Assay test groups in order of activity, high to low. 
 
Fig 5.  Lysozyme activity of sample and control groups.  Steeper drop in OD indicates higher activity.  
Samples 1-5 conditions are listed in the table above, with Sample 5 receiving harshest treatment and 
Sample 1 the mildest.   
Black squares:  cell control.  Red Circles:  Treatment #5.  Blue Triangles:  #4.  Green Triangles:  #3.  
Orange Diamonds: #2.  Purple Pentagons:  #1.  Brown Hexagons:  LZ Control.   n=4 
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By appearance on Figure 5, Samples 1-3 retained most activity, while samples that were 
exposed to PBS pH 1.5 in the stomach incubation lost more activity.  Groups 4 and 5, 
representing harsh digestion conditions, retained an estimated 10% of lysozyme activity 
when compared to lysozyme control.  When compared to the very mild conditions of 
Group 1, Groups 4 and 5 retained an estimated 30% of lysozyme activity.  This suggests 
that if a protein drug was loaded into a pellet and taken orally, it would retain some 
activity upon reaching inflammation sites within the colon. 
 
Fig. 6:  Initial rate of lysozyme activity for all samples, in terms of OD/min.  By this measure the most 
severe treatment group has one-third activity compared to the LZ control.  n=4 
 
By measure of the initial slope, it would seem that lysozyme from the Treatment #5 has 
one-third activity compared to the fresh lysozyme control.  Still, from Fig. 5 it appears 
that Treatment #5 lags and the pellets are not sufficiently protected from acid.  It's not 
possible to say whether the quality of coating is to blame or if the material itself does not 
perform in this manner. 
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Antibody Protection Study 
Negative controls without primary antibody showed nearly no staining, and while the 
antibody sample treated without gel protection was detectable it was comparable to the 
negative control and far fainter than positive control of identical concentration.  MUC1 
antibody would not survive digestion without the aid of protective matrices, as seen in the 
following image set. 
 
  
Fig. 7: Clockwise from top left:  Positive Control, Negative Control, Unprotected Antibody.  Negative 
Control shows some nonspecific staining, but Unprotected Antibody is slightly brighter.  Both pale in 
comparison to Positive Control, indicative of the damage an antibody experiences in unprotected digestion. 
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Mean intensity was calculated over the area of complete cells.  Again this shows a 
difference between unprotected antibody and negative control, but it is far below the 
positive control. 
 
Fig. 8:  Mean intensities using free antibody (Positive), antibody subjected to digestion simulation 
(Treated), and images without primary antibody (Negative).  While some antibody activity was observed in 
Treated samples, the damage was substantial when compared to the Positive control. 
 
All samples from pellet digestion and dissolution exhibited green staining, indicating the 
antibody had retained activity while the unprotected antibody above did not.  This 
indicates once again the ability of the pellet to protect delicate peptides, and furthermore 
demonstrates the possibility of immunotargeting with MUC1 conjugates.   Sample 2 used 
a stomach incubation with pH 4.0 to simulate use of antiacid.  In the images gathered 
sample 2 was consistently successful, but sample 1 was also labeled sufficiently so an 
antacid regimen seemed unnecessary, although later studies would suggest antacids to be 
helpful. 
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       A           B 
   
     C           D 
  
       E    
  
Fig. 9:  Confocal images of MUC1 
binding using primary antibody from 
pellets after digestion simulations.   
A:  Positive control.  
B:  Negative control.  
C:  pH 7.0 and no trypsin treatments 
D:  pH 4.0 and .1% trypsin 
E.  pH 1.5 and .1% trypsin 
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When comparing mean intensity values, we see that all the treatment groups faired 
similarly to the positive control with antibody activity mostly intact even in Sample 1 
with the harshest conditions. 
 
 
Fig. 10:  Mean Intensity of cells from each sample.  By this measure the antibody is retaining activity 
against all digestion simulations. 
 
This demonstrates the feasibility of orally delivering antibody drugs to the colon.  If this 
level of antibody protection can be applied in vivo, oral formulation of Infliximab and 
similar drugs will certainly be possible. 
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In Vivo:  Mouse Colitis Model 
Colitis model mice that were subjected to DSS regime lost an average of 12.5% body 
weight, while mice receiving CR2crry pellets lost only 5% and mice receiving the antacid 
drug omeprazole along with the CR2crry pellets did not lose weight.  As weight loss and 
malnutrition are symptoms of colitis, the anti-inflammation properties CR2crry appear to 
remain intact through oral delivery, especially in conjunction with omeprazole. 
 
Fig. 11:  Weight of mice over duration of test from before treatment/DSS (day -1) to sacrifice 
 (day 5).  DSS indicates colitis model and  omeprazole indicates antacid use.  Lack of weight loss 
indicates lack or remission of colitis symptoms.  n=6 
 
 
The same data is shown below in terms of total percentage weight change.  CR2crry 
alone significantly mitigated the weight loss compared to DSS controls, but CR2crry with 
antacid did much better and had as little weight change as the sham controls.  In this 
respect, oral delivery of CR2crry was successful when antacid was given simultaneously.  
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Shortening of the colon was severe in the DSS control group, losing about 40% of length 
compared to the sham group.  In this measure the CR2crry pellets alone showed little 
effect, but with the addition of antacid colon shortening was much mitigated.  Colon 
length data in Fig 13 demonstrates the benefit of administering antacids along with the 
peptide loaded pellets.  It may be possible that some small flaws existed in the acrylic 
coating of the CR2crry pellets, and had the CR2crry pellets been coated by industrial 
sprayers rather than manual methods they would perform comparably to the manually 
prepared pellets with antacid.  
*:  p<.05 
**:  p<.01 
***:  p<.001 
Fig. 12:  Total percent weight change 
of mice.  Both CR2crry groups 
experienced far less weight loss than 
their respective untreated DSS 
controls, and CR2crry reduced weight 
loss to zero when antacid was added.  
n=6 
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Colon tissue samples taken after sacrifice were stained with H&E and scored using a 
cumulative scale using three parameters:  
1.  Severity of inflammation (0, none; 1, slight; 2, moderate; 3, severe),  
2.  Depth of injury (0, none; 1, mucosal; 2, mucosal and submucosal; 3, 
 transmural),  
3.  Crypt damage (0, none; 1, basal one-third damaged; 2, basal two-thirds 
damaged; 3,  only surface epithelium intact; 4, complete loss of crypt and 
epithelium) 
These scores were added for each sample forming a 10-point scale.  Representative 
images are shown below. 
*:  p<.05 
**:  p<.01 
***:  p<.001 
Fig. 13: Average colon length at 
sacrifice.  Colon shortening was 
largely mitigated by the CR2crry with 
antacid, with very high significance 
compared to all controls and other 
treatments.  n=6 
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Fig. 14:  Representative colon sections stained by H&E.  A: Sham,  B: Pellet Control,  C: DSS,  D: DSS + 
antacid,  E:  DSS + CR2crry pellet,  F:  DSS + CR2crry pellet + antacid.  These images were used to assign 
histological scores of tissue damage and inflammation. 
 
A B 
C D 
E F 
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Once again the group given CR2crry pellets administered with antacid proved as healthy 
as the sham group.  Without antacid the benefit of CR2crry on histological score was not 
statistically significant.  This confirms the advantages of using antacids with peptide 
drugs, or otherwise the need for a more consistent acrylic coating.  When administered 
with an antacid, orally administered CR2crry pellets mitigated all measured colitis 
symptoms to the level of sham groups. 
 
CHAPTER 4:  CONCLUSIONS 
The oral format is the most familiar, convenient, and safe way for patients to be 
medicated on a daily basis, and the experiments recorded here build the case that it will is 
feasible to orally deliver peptide drugs while retaining a useful amount of activity.  The 
Fig 14:  Cumulative histological 
scores.  Scores of severity of 
inflammation, depth of injury, and 
crypt damage were added together to 
form a 10-point scale, with 10 
exhibiting the most damage.  Control 
groups showed much damage, while 
CR2crry with antacid was comparable 
to sham groups.  n=6  **p<.01 
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coated hydrogels of modified dextran provided a drug release profile well-localized and 
well-dispersed, releasing under colon conditions over a course of at least 24 hours. The 
protective system also provided enough protein protection to support measurable enzyme 
activity after digestion simulation, with over 30% lysozyme activity observed. 
 
Upregulation of glycoprotein MUC1 during inflammation may be present in CD and 
colitis lesions which would warrant the use of MUC1 immunotargeting for drug 
conjugates.  This specific antibody-antigen combination was investigated and found to 
work well when provided the protection of the pellet.  Future work may aim to determine 
the strength of affinity this immunotargeting can provide and to what degree drug 
nanocarriers could be retained in the glycohalyx of affected cells.  Other targeting 
strategies relevant to IBD include macrophage targeting with cd86 and epithelial cell 
adhesion molecules such as ICAM-1, which may be worth investigating as variations in 
this project. 
 
In vivo studies gave preliminary evidence that complex proteins can be delivered orally 
and remain effective.  When combined with antacid, orally delivered CR2crry mitigated 
the weight loss, shortening of the colon, and intestinal inflammation associated with 
ulcerative colitis.  Future work in this regard would focus on improving resistance to acid 
provided by the coated pellet, likely by improving the coating process to industrial 
standards.  It would also be interesting to repeat this experiment using a commercially 
available drug like Infliximab. 
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This opens the possibility of clinical translation for a great wealth of hormones, cellular 
signals, genetic sequences, and other macromolecules that have been recently 
investigated for clinical use.  Oral administration will aid convenience and compliance 
while avoiding the deleterious effects of systemic injection.  With colonic drug delivery, 
IBD is possibly the disease most directly benefited but it may be determined that many 
protein drugs are better absorbed in the mild proteolytic conditions of the large intestine 
rather than the small intestine.  In either case the mastery of oral delivery targeting the 
colon, complete with proven peptide protection, has immense therapeutic potential. 
 
Future work on this project should include administering Infliximab in vivo and 
improving the pellet coating by using proper sprayer or bed coating equipment.  Alternate 
targeting moieties and nanomaterial conjugations are other interesting aspects. 
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